Reaktionsgleichung
[Br:1][C:2]1[C:3](Cl)=[N:4][CH:5]=[C:6]([CH:22]=1)[C:7]([NH:9][C:10]1[CH:15]=[CH:14][C:13]([O:16][C:17]([F:20])([F:19])[F:18])=[C:12]([F:21])[CH:11]=1)=[O:8].[NH:24]1[CH2:28][CH2:27][C@H:26]([CH2:29][OH:30])[CH2:25]1>>[Br:1][C:2]1[C:3]([N:24]2[CH2:28][CH2:27][C@H:26]([CH2:29][OH:30])[CH2:25]2)=[N:4][CH:5]=[C:6]([CH:22]=1)[C:7]([NH:9][C:10]1[CH:15]=[CH:14][C:13]([O:16][C:17]([F:20])([F:19])[F:18])=[C:12]([F:21])[CH:11]=1)=[O:8]Komponenten
3
Versuchsvorschrift
The title compound was prepared in an analogous fashion to that described in Stage 33.1 using 5-bromo-6-chloro-N-(3-fluoro-4-(trifluoromethoxy)phenyl)nicotinamide (Stage 198.2) and (S)-1-pyrrolidin-3-yl-methanol to afford an off-white crystalline solid. HPLC (Condition 4) tR=5.99 min, UPLC-MS (Condition 3) tR=1.18 min, m/z=478.1/480.1 [M+H]+.
Aufarbeitung
- customto afford an off-white crystalline solid
Quellen und Nachweise
- ORD-Eintrag
- ord-c9b356c7ae4c4a49b309fb2d2d8f9e71
- Quelldatensatz
- uspto-grants-2016_03
- Patentnummer
- US09278981B2
Verknüpfte Notizen
Wird geladen…